Share This Page
Drugs in ATC Class L01XM
✉ Email this page to a colleague
Drugs in ATC Class: L01XM - Isocitrate dehydrogenase (IDH) inhibitors
| Tradename | Generic Name |
|---|---|
| IDHIFA | enasidenib mesylate |
| TIBSOVO | ivosidenib |
| REZLIDHIA | olutasidenib |
| VORANIGO | vorasidenib |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class L01XM: Isocitrate Dehydrogenase (IDH) Inhibitors
IDH inhibitor competition is split between IDH1 and IDH2 drugs, with early-mover pricing and trial-driven label expansion shaping near-term revenue. Patent protection is dominated by compound, composition-of-matter, and method-of-use estates tied to IDH1/IDH2 inhibition, mutant-specific biomarkers, and combination regimens. The next wave of generic and biosimilar risk is concentrated in the first generation of oral IDH small molecules, with Paragraph IV timing tied to each product’s patent cliff and any pediatric/conditional exclusivity overlays.
| Segment | Target | Key US commercial molecules (examples) | Primary IP estate drivers |
|---|---|---|---|
| IDH1 inhibitors | R132 mutant IDH1 | ivosidenib (IDH1) | Compound + mutant-selective use; formulation/combination additions |
| IDH2 inhibitors | R140/R172 mutant IDH2 | enasidenib (IDH2) | Compound + mutation-selective indication; subsequent line/combination claims |
| Next-gen / pipeline | IDH1 or IDH2 | (varies by sponsor) | Follow-on analogs, resistant mutants, next-gen dosing and combos |
Scope note: L01XM is a large class label. The patent and market dynamics below focus on the major commercial IDH1/IDH2 inhibitor framework that drives most ATC L01XM revenue exposure, with emphasis on how estates typically structure exclusivity and how generic entry risk is evaluated in practice.
What patents protect IDH1 and IDH2 inhibitors (ATC L01XM) in the US?
Answer: Primary protection is a layered mix of compound (small-molecule structure), compositions (salts, polymorphs, particle size, solid forms), and method-of-treatment claims (mutant genotype, disease stage, line of therapy, and combination regimens). Patent scope often narrows over time as litigation and USPTO actions remove or limit claims.
Which patent types dominate the IDH inhibitor estate?
- Compound and substructure claims
- Core scaffold claims around IDH1 R132 inhibitors and IDH2 R140/R172 inhibitors.
- Variant claims covering analogs, stereochemistry, salts, and hydrates.
- Composition-of-matter
- Capsules/tablets and solid-state form claims (e.g., specific crystalline forms).
- Salt forms and formulation stability claims (bioavailability-linked attributes).
- Method-of-use (treatment) claims
- Treatment of AML or related myeloid malignancies with confirmed IDH1/IDH2 mutations.
- Use in first-line vs relapsed/refractory settings.
- Combination methods (IDH inhibitor + hypomethylating agent, chemotherapy, or venetoclax-class regimens depending on sponsor trials).
- Manufacturing method patents
- Less frequent for small molecules than formulation and method-of-use, but present for specific intermediates, crystallization controls, and purification.
How many patents cover an IDH inhibitor product in practice?
Estates for oncology small molecules commonly include:
- 10 to 30 active US patents at brand maturity across compound, formulation, and method-of-use families.
- A subset of 3 to 10 “likely-to-infringe” patents typically anchors Orange Book listings and litigation leverage, particularly for method-of-use claims tied to the FDA label.
Key patent holders and assignee patterns
- Original inventors tend to remain assignees within early families (compound and first use).
- Follow-on estates are often reassigned or co-assigned through corporate restructurings or licensing.
Which Orange Book patents list for IDH1 inhibitors like ivosidenib and IDH2 inhibitors like enasidenib?
Answer: Orange Book listings usually include multiple mechanism-linked patents for drug substance and formulation, plus method-of-use patents that correspond to FDA-approved indications. Exact listings and expiration dates are product- and NDA/label-specific.
How to interpret Orange Book status for IDH inhibitors
Orange Book listings for an IDH inhibitor should be reviewed by:
- Patent type (drug substance, drug product, use).
- Claim scope (mutant genotype requirement; combination language).
- Expiration basis (term adjustment, patent term extension).
- Regulatory exclusivity overlays (5-year new chemical entity, 7-year orphan drug if applicable, and pediatric exclusivity if triggered).
What matters for generic risk
Generic entry risk is driven by:
- Which listed patents are still unexpired on the filing date of the ANDA.
- Whether the ANDA filer can file a Paragraph IV certification against each unexpired patent.
- How courts construe the mutant-specific and regimen-specific language in method-of-use claims.
When do IDH inhibitors lose exclusivity in the US (patent expiration and exclusivity windows)?
Answer: Loss of exclusivity occurs in staggered steps: first by patent expirations (compound and formulation) then by method-of-use claim protection and regulatory exclusivity expiration. The practical “ready for generic” date often aligns with the last-remaining unexpired, likely-to-infringe Orange Book patent for the approved indication and dosage form.
Typical IDH inhibitor exclusivity timeline structure
- Initial compound patent: longest term, often earliest cliff.
- Follow-on formulation or polymorph patents: extend protection by claim-specific drug product attributes.
- Method-of-use patents: can extend market exclusivity by covering specific patient subgroups (mutant genotype confirmation) or specific treatment lines.
- Regulatory exclusivity: may add time beyond patent expiration for new indications, especially where the product receives new orphan designations or major label expansions.
How to translate dates into generic launch scenarios
A generic filer needs:
- At least one pathway to avoid infringement (non-infringement or invalidity) for each Paragraph IV target.
- A post-approval manufacturing and labeling plan that fits the protected indication language.
- Clearance on bioequivalence and any labeling carve-outs if a partial judgment is entered.
What Paragraph IV challenges have targeted IDH inhibitors and what were the outcomes?
Answer: Paragraph IV challenges typically target method-of-use patents first when compound protection is older and less likely to provide an enforceable barrier. Outcomes vary with claim construction and factual infringement over mutant-genotype inclusion criteria.
Why method-of-use patents get targeted
- They are often listed for the approved indication and dosing regimen.
- Labeling language creates a direct infringement narrative for ANDA labels mirroring the protected regimen.
- Competing ANDA labels can become a “design-around” bottleneck if the brand method-of-use claims use narrow language (e.g., specific mutation type or line of therapy).
How settlements usually shape market entry
Common settlement patterns in oncology small molecules include:
- “No-entries” or delayed entry through a mutually agreed date.
- Design-around labeling carve-outs where the generic launches in a narrower indication if allowed by court outcomes.
- Royalty-bearing license (less common for brand strategy in some estates, more common where the brand prefers predictable revenue sharing).
How strong is the patent estate for IDH inhibitors (overall enforceability and litigation risk)?
Answer: The strength is usually highest where method-of-use claims are specific to patient genotype confirmation and treatment context. Estates weaken where claims are broad enough to be invalidated for obviousness or where design-around labeling is feasible.
Key strength drivers
- Claim specificity: mutant genotype confirmation and regimen specificity reduce easy design-around.
- Independent claim coverage: multiple claim sets across compound, formulation, and method-of-use reduce single-point failure.
- Litigation history: repeated defenses and sustained injunction outcomes correlate with higher enforceability.
Key weakness drivers
- Prior art overlap: early IDH mutant biology and lead compounds can create invalidity pressure for follow-on analogs.
- Narrow evidence of nonobviousness: if follow-on claims depend on properties considered routine at filing time, courts can narrow or invalidate.
- Claim construction risk: if “requires” language is interpreted as not limiting in the ANDA label, infringement can fail.
What formulations are protected for IDH inhibitors (polymorphs, salts, particle size, and dosing forms)?
Answer: Formulation protection for IDH inhibitors typically covers solid-state form (crystalline forms), salt/hydrate variants, and manufacturing controls tied to stability and bioavailability. These patents often support Orange Book “drug product” listings.
Common formulation claim themes
- Specific crystalline polymorphs with defined X-ray diffraction patterns or thermal profiles.
- Salt forms with improved solubility or stability.
- Granulation and milling controls that influence dissolution and absorption.
- Container-closure or storage stability claims for specific dosage forms.
Why formulation patents matter even if compound patents expire
Even with expired compound patents, a generic may still be blocked if:
- The generic must use a protected solid form (or cannot prove equivalence/entry via a non-infringing form).
- The protected formulation is required for the label dose and bioequivalence package.
How do IDH inhibitor patents cover combinations (hypomethylating agents, venetoclax, chemotherapy)?
Answer: Combination method-of-use claims are a major lever for extending IDH inhibitor exclusivity into expanded lines of therapy. Courts focus on whether the ANDA label includes a protected regimen.
Combination claim structures seen in practice
- “A method of treating… comprising administering IDH inhibitor to a patient…”
- “wherein the patient has…” mutation status
- “in combination with…” a defined partner drug and dosing window
Generic design-around routes
- Launch the generic with a narrower label that excludes the protected combination language.
- Use FDA-approved label differences if the brand’s method-of-use claims are narrow and the generic’s instructions omit essential regimen elements.
What generic entry risks exist for IDH inhibitors by route of administration and patient population?
Answer: The largest generic entry risk is for approvals that can be immediately labeled with the same indication and regimen language. Where exclusivity blocks the approved label, the main risk is delayed entry or limited label carve-outs.
Risk categories
- High-risk patents
- Method-of-use patents that map directly to the current FDA label.
- Moderate-risk patents
- Formulation patents that can sometimes be bypassed by a non-infringing solid form.
- Lower-risk patents
- Process/intermediate patents that are harder to prove for infringement unless manufacturing methods are implicated.
Patient population constraints
Genotype-qualified indications tend to reduce generic labeling flexibility. If the brand requires mutation confirmation in instructions, generics face greater labeling and infringement friction.
Which companies are challenging IDH inhibitor patents (and what are their typical tactics)?
Answer: Generic filers typically use Paragraph IV certifications against a subset of listed patents most likely to be attacked successfully, then negotiate settlements or rely on claim narrowing in litigation. Final tactics depend on which patents remain listed at filing.
Common challenger behaviors
- Certify non-infringement for method-of-use claims based on label differences.
- Assert invalidity on obviousness and anticipation grounds for follow-on formulation and analog families.
- Seek early case resolution to trigger an at-risk launch only after final appellate or stipulated dates.
How does the IDH1 inhibitor market compare with the IDH2 inhibitor market (commercial and IP exposure)?
Answer: IP exposure differs by drug maturity and the number of label expansions. In general, IDH1 inhibitors with broader ongoing trials can have more follow-on method-of-use protection tied to expanded regimens, while IDH2 drug estates can show heavy reliance on mutation-specific indication language.
What to monitor by sponsor strategy
- Label expansions and post-approval studies that create new method-of-use claim targets.
- Manufacturing transfer agreements that can reduce generic design-around feasibility.
- Patent filings that track clinical evidence for combinations, dosing modifications, and sequencing.
What FDA regulatory status matters for IDH inhibitors in patent battles (NDA type, exclusivity, and label scope)?
Answer: Exclusivity and labeling scope govern infringement narratives. FDA label inclusion of mutation confirmation and regimen instructions can determine whether an ANDA label “practices” a method-of-use claim.
Key regulatory status elements
- NDA/BLA pathway (small molecule vs supplement scope).
- Orphan drug designation effects on regulatory exclusivity.
- Pediatric exclusivity triggers where applicable.
- Labeling breadth from initial approval and subsequent supplements.
How do settlement agreements affect timing for generic launch of IDH inhibitors?
Answer: Settlements usually convert litigation uncertainty into a fixed entry date or a license with payment and labeling constraints. They can also include covenants not to sue during the restricted period.
Settlement clauses to look for in practice
- Entry date triggers based on patent expiration.
- Design-around approval language permitted/required for the generic.
- License scope limited to specific patents, formulations, or indications.
- “Use restrictions” matching claim limitations.
Key Takeaways
- IDH inhibitor IP estates are layered: compound + drug product + method-of-use, with method-of-use frequently dictating practical generic entry timing.
- Orange Book listings and their remaining legal status determine whether Paragraph IV challenges can realistically block entry or yield design-around launches.
- Market dynamics are driven by label expansions and regimen adoption, which in turn expand the set of enforceable method-of-use claim targets.
- Formulation patents can extend protection even after compound cliffs, especially when protected solid-state forms align with bioequivalence requirements.
- Settlement agreements commonly replace litigation outcomes with predictable launch dates and labeling constraints.
FAQs
1) Which patent categories usually extend IDH inhibitor exclusivity beyond the original compound expiry?
Follow-on method-of-use and drug product (solid form) patents are the dominant extension mechanisms.
2) What ANDA label elements create infringement exposure for IDH inhibitor method-of-use claims?
Label instructions that include mutant genotype qualification and the protected combination regimen or treatment line.
3) How do mutation-specific indications affect generic “design-around” for IDH inhibitors?
Mutation-specific requirements reduce labeling flexibility and increase infringement risk when the generic label mirrors the approved genotype language.
4) Do formulation patents meaningfully delay IDH inhibitor generics after compound expiry?
Yes, when the protected solid form is required for the generic bioequivalence package or the generic cannot use a non-infringing form.
5) What is the most common settlement endpoint in IDH inhibitor patent disputes?
A delayed entry date tied to patent expiration, often combined with labeling restrictions or a limited license.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- U.S. Code. (n.d.). 35 U.S.C. § 271 (infringement) and related provisions.
- FDA. (n.d.). Exclusivity Determinations for Drugs. U.S. Food and Drug Administration.
More… ↓
